The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
暂无分享,去创建一个
[1] C. D. Atkins. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2003, Journal of the National Cancer Institute.
[2] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[3] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Cleeland,et al. Validation of the German version of the Brief Pain Inventory. , 1999, Journal of pain and symptom management.
[5] M. Jensen,et al. Pain‐Specific Beliefs, Perceived Symptom Severity, and Adjustment to Chronic Pain , 1992, The Clinical journal of pain.
[6] K. Pienta,et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.
[7] R H Brook,et al. Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.
[8] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[9] L. Dogliotti,et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.
[10] C. Cleeland,et al. Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.
[11] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[12] R. Pelger,et al. Strategies for Management of Prostate Cancer-Related Bone Pain , 2001, Drugs & aging.
[13] H. Villavicencio. Quality of life of patients with advanced and metastatic prostatic carcinoma. , 1993, European urology.
[14] G. Andriole,et al. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.
[15] Ana Ivelisse Avilés,et al. Linear Mixed Models for Longitudinal Data , 2001, Technometrics.
[16] P. Lachenbruch. Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .
[17] K. Anstrom,et al. Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Libshitz,et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. , 1998, Journal of pain and symptom management.
[19] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[20] M. Rosenthal. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2003, Journal of the National Cancer Institute.